What Is the Life Expectancy After a TAVR Procedure?

Most people who undergo TAVR (transcatheter aortic valve replacement) can expect to live for years afterward, though survival depends heavily on age, overall health, and surgical risk at the time of the procedure. National registry data show roughly 70% of patients are alive at five years and about 42% at ten years after a transfemoral TAVR, though those numbers shift dramatically depending on who is getting the valve and how healthy they were beforehand. The answer is rarely a single number, and the factors shaping it are worth understanding.

What the Survival Numbers Actually Show

Survival statistics after TAVR vary because different studies draw from different patient pools. Early TAVR trials enrolled very sick, elderly patients who had no surgical option, which produced grimmer numbers. More recent data reflect a broader range of patients, including lower-risk individuals in their seventies. A large national registry analysis of transfemoral TAVR found estimated overall survival of about 70% at five years and 42% at ten years.¹ A meta-analysis pooling data from eleven earlier studies, where the average patient age was 82 and many were higher risk, found lower survival: about 48% at five years and 12% at ten years.²

The gap between these figures reflects how quickly the field has changed. The meta-analysis captured an era of sicker patients and first-generation devices, while the registry study captured more contemporary practice. For patients treated today, the registry figures are more representative, though even those are averages smoothing across many different health profiles.

For low-risk patients specifically, five-year outcomes look even better. In the landmark Evolut Low Risk trial, all-cause mortality after TAVR was about 13.5% at five years, meaning roughly 86 or 87 out of every 100 low-risk patients were alive five years later.³ Those numbers are strikingly good for a heart procedure, though they still trail the survival you would expect in the general population of similar age.

Why Survival Still Falls Short of the General Population

Even among lower-risk patients, TAVR recipients tend to die sooner than age-matched people without aortic stenosis. A study comparing TAVR patients to the general population found that five-year survival was about 64% for low-risk TAVR patients (average age 78) versus 81% for the general population, and about 66% for intermediate-risk patients (average age 83) versus 71% in the general population.⁴ The gap was smaller for the older intermediate-risk group, partly because aging itself narrows the survival difference.

This shortfall is not really about the valve procedure failing. Severe aortic stenosis is a marker that cardiovascular disease has been building for years, and that disease does not vanish when the valve is replaced. Many TAVR patients also carry other conditions, including kidney disease, diabetes, lung disease, and frailty, that affect how long they live regardless of whether the new valve works perfectly.

The Factors That Shift the Odds Most

Several conditions at the time of TAVR carry outsize influence on how long someone survives afterward.

Frailty and poor mobility stand out. Patients who are physically frail before TAVR have higher one-year mortality and tend to get less symptom relief from the procedure.⁵ This makes intuitive sense: if someone’s overall physiological reserve is depleted, fixing the valve helps the heart but does not restore the body’s broader resilience. Diabetes, chronic kidney disease, and male sex were also linked to increased one-year mortality in the same research.

Kidney function deserves particular attention because it can change during the procedure itself. When kidney function worsens after TAVR and does not recover before discharge, the patient faces a tougher road. Higher contrast dye use during the procedure is associated with that kidney decline.⁶ This is one of many reasons heart teams try to minimize contrast use and monitor kidney function closely.

Needing a permanent pacemaker after TAVR is another long-term concern. It happens in a notable percentage of cases, and data from a Swiss registry showed that patients who required a pacemaker after TAVR had higher overall and cardiovascular death rates that persisted out to five and ten years, along with more heart-failure symptoms over time.⁷ Not everyone who gets a pacemaker does poorly, but the association is real enough that reducing pacemaker rates has become a major engineering and technique focus for the field.

What Actually Causes Death After TAVR

One of the more surprising findings in TAVR research is that more than half of deaths beyond the first thirty days are from non-cardiovascular causes. A systematic review found that in the early period (within a month), infections, heart failure, and multiorgan failure were the leading killers. Beyond that window, infections and heart failure remained prominent, joined by sudden death.⁸

As time passes, the proportion of deaths from heart-related causes falls. In a large study comparing TAVR patients to matched controls, cardiovascular deaths accounted for roughly 54% of deaths in the first year after TAVR but only about 33% among those who died more than seven years out.⁹ In other words, the longer someone survives after TAVR, the more likely they are to eventually die from cancer, infections, or other non-cardiac conditions rather than from their heart disease. This pattern underscores that long-term survival after TAVR depends on managing the whole patient, not just the valve.

How TAVR Compares to Open-Heart Surgery

For many patients, the relevant question is not just how long people live after TAVR but whether TAVR offers the same longevity as traditional surgical aortic valve replacement (SAVR). The short answer, supported by multiple randomized trials now extending to five years, is that survival is similar.

In low-risk patients, the Evolut Low Risk trial found five-year all-cause mortality of about 13.5% after TAVR versus about 13-15% after surgery, a difference that was not statistically meaningful.³ Similar results came from an analysis focused on isolated procedures (patients getting only the aortic valve, without other cardiac surgery), where five-year mortality was about 13.5% with TAVR and 12.8% with surgery.¹⁰

In intermediate-risk patients, the SURTAVI trial found essentially identical rates of death or disabling stroke at five years, about 31% with TAVR and 31% with surgery.¹¹ The higher absolute mortality in the intermediate-risk group compared to the low-risk group reflects the older, sicker patient population, not a difference between the two procedures.

Where the two approaches diverge is in their complication profiles. TAVR patients consistently have higher rates of permanent pacemaker implantation. In the SURTAVI trial, about 39% of TAVR patients needed a pacemaker at five years versus 15% of surgery patients.¹¹ TAVR also tends to produce somewhat more paravalvular leak, a small amount of blood flowing around the outside of the new valve. Surgical patients, on the other hand, face a longer recovery, higher early bleeding risk, and the full burden of open-chest surgery. For most patients, the tradeoffs wash out over five years in terms of survival, but the specific complications shape individual planning.

How Long the Replacement Valve Itself Lasts

Every bioprosthetic valve will eventually wear out. Whether the valve lasts longer than the patient is one of the key questions in TAVR, and the honest answer is that data are still maturing. Ten-year follow-up from first-generation devices showed that severe structural valve deterioration was relatively uncommon, occurring in roughly 4% of the overall study population, though rates differed by valve type.¹² In a separate long-term study with a median follow-up approaching six years, severe valve deterioration was found in under 1% of patients, while moderate deterioration was seen in roughly 9%.¹³

A separate concern is leaflet thrombosis, where blood clots form on the valve leaflets even when the valve is structurally intact. This can impair how the valve opens and closes and may contribute to earlier degeneration over time. The mechanisms are not entirely understood, but altered blood flow around the valve, the surface characteristics of bioprosthetic tissue, and patient-specific clotting tendencies all play a role.¹⁴ Anticoagulant or antiplatelet medications after TAVR are partly aimed at reducing this risk, and recent evidence supports using a single antiplatelet agent rather than dual therapy in patients who do not need blood thinners for other reasons, since the simpler approach causes less bleeding without increasing clotting events.¹⁵

For older patients in their eighties, the valve is very likely to last for the rest of their lives. The durability question becomes more pressing for younger patients in their sixties or seventies who may need the valve to function for fifteen or twenty years. That is where lifetime management planning enters the conversation.

What Happens When a TAVR Valve Eventually Fails

When a TAVR valve wears out, there are broadly two options: placing a new transcatheter valve inside the old one (redo TAVR, or “valve-in-valve”) or surgically removing the TAVR valve and replacing it with open-heart surgery. Redo TAVR is far less invasive and appears to have favorable short-term outcomes, with in-hospital mortality in the range of 0 to 2.3%.¹⁶ A U.S. registry analysis of redo TAVR using self-expanding valves found that clinical outcomes were similar to first-time TAVR at both 30 days and one year, and patients showed sustained improvements in functional status and quality of life.¹⁷

The catch is that not everyone is a candidate for redo TAVR. The feasibility depends on anatomy, particularly whether the coronary arteries would be blocked by a second valve sitting inside the first. Imaging-based simulation studies suggest a substantial portion of patients may not be eligible for a valve-in-valve approach based on the size and type of their original TAVR and their individual anatomy.¹⁶ For those patients, surgical explant of the old valve is an option, but it carries higher mortality that is partly driven by comorbidities, infection, and the technical difficulty of removing a TAVR valve.

This is why cardiologists increasingly talk about “lifetime management” for younger patients. The first valve choice can constrain what is possible down the road. Some teams recommend surgical valve replacement as the initial procedure for patients in their fifties or sixties, specifically because a surgical bioprosthetic valve tends to be easier to treat later with a transcatheter valve-in-valve, preserving more options over a decades-long time horizon.¹⁸

Quality of Life and Recovery

Survival numbers are important, but most patients also want to know whether they will feel better. On this front, the news is generally good. Meta-analyses have documented that quality of life and functional capacity improve after TAVR, and these improvements track similarly to what surgical patients experience.¹⁹ Most patients notice improvements in breathlessness and exercise tolerance within weeks of the procedure, reflecting the immediate relief of the narrowed valve being opened.

Cardiac rehabilitation can amplify those gains. A pilot study of home-based cardiac rehab after TAVR found significant improvements in physical functioning scores, with one measure of functional capacity improving from a median of 14.3 before the program to 24.2 afterward.²⁰ Cardiac rehab remains underused after TAVR compared to after surgical valve replacement, partly because many TAVR patients are older and have mobility limitations that make attending an outpatient program difficult. Home-based programs may help close that gap.

Cognitive function is a common worry, especially for older patients. The concern is reasonable given that TAVR involves threading a catheter through major blood vessels near the brain. But studies tracking mental performance after TAVR have been largely reassuring. One study following patients for two years found that 91% maintained stable cognitive performance throughout.²¹ Another found that average cognitive test scores actually improved slightly after TAVR, with persistent decline occurring in only a small minority.²² Some researchers believe the improvements reflect better blood flow to the brain once the valve obstruction is relieved, though the evidence for that mechanism is indirect.

Readmissions After TAVR

Hospital readmission is common after TAVR, and the reasons are not always what you might expect. In a study of over 1,000 patients who survived their initial hospitalization, about a third were readmitted for non-cardiac causes and about a fifth for cardiac causes during roughly two years of follow-up. The most frequent non-cardiac reasons were infections, gastrointestinal issues, and respiratory problems, while heart failure and irregular heart rhythms topped the cardiac list.²³ The risk of non-cardiac readmission was highest in the period right after discharge and gradually declined, while cardiac readmission remained relatively constant at about 1% per month throughout follow-up.

This pattern reinforces the earlier point about causes of death: TAVR patients are medically complex, and the valve procedure is just one piece of their health puzzle. Staying on top of infections, kidney health, and general medical care matters as much as valve follow-up for keeping patients alive and out of the hospital.

How Newer Devices Have Changed Outcomes

TAVR technology has evolved rapidly since the first procedures in the early 2000s. A meta-analysis comparing first-generation devices to newer models found that procedural mortality dropped from about 5.4% to 1.5% with next-generation valves, and stroke rates fell as well.²⁴ This means that older survival statistics, especially from the earliest trials, substantially underestimate how well current TAVR patients do. If you are looking at a study from 2012 or 2013, the devices and techniques used are a generation or more removed from what is available now.

Newer valve designs have also reduced paravalvular leak, which was a persistent problem with early devices. Better imaging, more precise sizing, and features like external sealing skirts have driven these improvements. Clinical experience introducing second-generation valves has confirmed that the transition to newer technology can be made safely without compromising patient outcomes.²⁵

Bicuspid Aortic Valves and TAVR

Some people are born with a bicuspid aortic valve, meaning two leaflets instead of the usual three. This anatomy was initially considered a relative contraindication for TAVR because the asymmetric shape made it harder to seat the replacement valve properly. Outcomes data have been catching up, though, and the picture is more favorable than early concerns suggested. A multicenter study following patients out to ten years found that all-cause mortality was comparable in bicuspid and tricuspid valve patients after TAVR.²⁶ A meta-analysis confirmed that device success and one-year survival rates were similar between the two groups.²⁷

That said, bicuspid patients may face a somewhat higher rate of pacemaker implantation after TAVR. Data from the Swedish SWEDEHEART registry found that bicuspid patients had about 1.8 times the odds of needing a pacemaker compared to tricuspid patients, even though mortality and most other complications were similar.²⁸ New-generation devices have also improved outcomes in bicuspid anatomy specifically; the multicenter study noted meaningfully lower mortality with newer valves compared to older designs in this subgroup.²⁶

Disparities in Who Does Well

TAVR outcomes are not uniform across demographic groups, and emerging research has highlighted important disparities. A study of in-hospital outcomes found that women had about a third higher odds of in-hospital mortality compared to men, along with higher rates of bleeding and vascular complications, though they were less likely to need a pacemaker. Hispanic patients had nearly twice the odds of in-hospital mortality compared to non-Hispanic white patients, and Black patients had roughly double the odds of stroke. Hispanic women specifically faced the highest mortality odds.²⁹

The reasons for these disparities are likely multifactorial, involving differences in vascular anatomy, body size, the timing and severity of disease at presentation, comorbidity burden, and access to high-volume TAVR centers. Interestingly, a study examining longer-term outcomes across racial groups found that overall mortality was similar between men and women after adjustment, though the risk of stroke remained higher in women, particularly in non-Asian populations.³⁰ The gap between worse in-hospital outcomes and comparable longer-term mortality for women suggests that the periprocedural period is where the disparity concentrates, which could potentially be addressed through better tailoring of device sizes and access-site management for smaller-bodied patients.